【レポートの概要（一部）】
1. Report Overview
1.1 Overview of the World Market for Ovarian Cancer Treatment
1.2 Why You Should Read This Report
1.3 How This Report Delivers
1.4 Main Questions Answered by This Analysis
1.5 Who Is This Study For?
1.6 Methods of Research and Analysis
1.7 Frequently Asked Questions (FAQs)
1.8 Some Associated Reports
1.9 About Visiongain
1.10 Abbreviations Frequently Used in This Report
2. An Introduction to Ovarian Cancer Therapy
2.1 Overview of Ovarian Cancer
2.1.1 Symptoms of Ovarian Cancer
2.1.2 Risk Factors for Ovarian Cancer
2.1.3 Global Prevalence and Incidence of Ovarian Cancer
2.2 Diagnosing Ovarian Cancer
2.2.1 Laboratory Testing: The Uncertainty of CA 125 Testing
2.2.2 The Potential of Lysophosphatidic Acid Assay for Early Stage Ovarian Cancer
2.2.3 Imaging Studies for Diagnosing Ovarian Cancer
2.3 Treatment Options for Cancer
2.3.1 Chemotherapy
2.3.2 Targeted Therapy
2.3.3 Immunotherapy: Fastest Growing Sector in Cancer Therapy
2.3.3.1 Monoclonal Antibodies (mAbs)
2.3.3.2 Cancer Vaccines
2.3.3.3 Non-Specific Immunotherapies
2.3.4 Hormone Therapy
2.3.5 First-Line Therapy: Platinum-Taxane Treatment
2.3.6 Second-Line Therapy
2.3.7 Maintenance Therapy
3. Ovarian Cancer: World Market 2015-2025
3.1 Ovarian Cancer Therapies Market, 2014
3.1.1 A Note on Monoclonal Antibodies in this Report
3.2 Ovarian Cancer Therapies Market Forecast, 2015-2025
3.3 Driving and Restraining Forces Affecting the Ovarian Cancer Therapy Market
3.3.1 Increasing Patient Population
3.3.2 Intense Competition from Generics
3.4 The Ovarian Cancer Therapy Submarket Shares, 2019 and 2025
3.5 The Future of the World Market for Ovarian Cancer Therapy by Therapeutic Class: Grouped Revenue Forecasts, 2014-2025
3.5.1 Targeted Therapy—Leading Submarket in Ovarian Cancer Therapy by 2025
3.5.2 Chemotherapy—Remains First-Line Treatment for Ovarian Cancer
3.5.3 Immunotherapy—The Fastest Growing Segment in Cancer Therapy
3.5.4 Hormone Therapy—Rare Treatment in Ovarian Cancer
4. Leading Ovarian Cancer Drugs 2014
4.1 Avastin (Roche/Chugai) – The World Market Leader
4.1.1 Avastin Revenue, 2010-2014 – Mixed Growth
4.1.2 Avastin Ovarian Cancer Forecast, 2015-2025
4.2 Lynparza (AstraZeneca)
4.2.1 Lynparza Forecast 2015-2025
4.3 Yondelis (Zeltia/Johnson & Johnson)
4.3.1 Yondelis (Zeltia/Johnson & Johnson): Historical Revenues
4.3.2 Yondelis Forecast 2015-2025
4.4 Other Ovarian Cancer Therapies
5. Leading Regional and National Markets in the Ovarian Cancer Therapy 2015-2025
5.1 Regional Breakdown of the World Ovarian Cancer Therapeutics Market
5.1.1 How Will Regional Market Shares Change to 2025?
5.2 The US Ovarian Cancer Drug Therapy Market, 2014
5.2.1 US Ovarian Cancer Therapeutics Market Forecast, 2015-2025
5.3 The Ovarian Cancer Therapy Market in the EU5 Markets to 2025
5.3.1 German Ovarian Cancer Therapy Market Forecast, 2015-2025
5.3.2 French Ovarian Cancer Therapy Market Forecast, 2015-2025
5.3.3 UK: Pharmaceutical Price Regulation Scheme and Market Forecast, 2015-2025
5.3.3.1 NICE: Guidance for Ovarian Cancer Therapies
5.3.4 Spanish Ovarian Cancer Therapy Market Forecast, 2015-2025
5.3.5 Italian Ovarian Cancer Therapy Market Forecast, 2015-2025
5.4 Japan: Growth in Generics – Ovarian Cancer Therapy Market Forecast, 2015-2025
5.5 Chinese Ovarian Cancer Therapy Market Forecast, 2015-2025
5.6 Indian Ovarian Cancer Therapy Market Forecast, 2015-2025
5.7 Brazilian Ovarian Cancer Therapy Market Forecast, 2015-2025
5.8 Russian Ovarian Cancer Therapy Market Forecast, 2015-2025
6. Leading Companies in the Ovarian Cancer Therapy Market
6.1 Companies with Exclusivity in 2014
6.2 Johnson & Johnson (J&J)
6.2.1 Sales and Performance Analysis, 2014
6.2.2 Pharmaceutical Segment Sales Analysis, 2014
6.2.2.1 R&D Performance Analysis, 2014
6.2.3 Recent M&A Activity: J&J Acquires Alios BioPharma and Aragon Pharmaceuticals
6.3 Roche
6.3.1 Sales and Performance Analysis, 2014
6.3.2 Pharmaceutical Segment Sales Analysis, 2014
6.3.2.1 Cancer Drug Sales and Performance Analysis, 2014
6.3.2.2 Pharmaceutical Segment R&D Performance Analysis, 2014
6.3.3 Recent M&A Activity
6.4 AstraZeneca
6.4.1 Sales and Performance Analysis, 2014
6.4.2 Pharmaceutical Segment Sales Analysis, 2014
6.4.2.1 Cancer Drug Sales and Performance Analysis, 2014
6.4.2.2 R&D Performance Analysis, 2014
6.4.3 Recent M&A Activity: The Pfizer and AstraZeneca Saga
7. Ovarian Cancer Therapy: Developmental Pipelines 2015
7.1 Ovarian Cancer Phase III Candidates 2015
7.1.1 Niraparib (TESARO): Leading the PARP Inhibitors in the Pipeline
7.1.1.1 TESARO and Merck to Collaborate: Niraparib and Keytruda
7.1.2 Trebananib (Amgen/Takeda Pharmaceuticals): Misses Key Survival Measure in Phase III
7.1.3 Nintedanib (Boehringer Ingelheim): Triple Angiokinase Inhibitor
7.1.4 Recentin (AstraZeneca): Promising Results in Phase III
7.1.5 Rucaparib (Clovis Oncology): ARIEL2 and ARIEL3
7.1.6 Opaxio (CTI BioPharma): Biologically Enhanced Chemotherapeutic
7.1.7 Binimetinib (Array Biopharma): Expected Filing in 2016
7.1.8 Lurbinectedin (PharmaMar): Second-Generation Analogue of Yondelis (Trabectedin)
7.1.9 Virgil (Gradalis): Autologous Tumour Cell Vaccine
7.1.10 Farletuzumab (Eisai): Failure in Phase III
7.2 Ovarian Cancer Phase II Candidates 2015
7.2.1 CVac (Prima BioMed): MUC-1 Cancer Vaccine
7.2.2 SG2000 (Spirogen): Cytotoxic Technology Based on Pyrrolobenzodiazepines
7.2.3 Zoptarelin Doxorubicin (Aeterna Zentaris): Luteinising Hormone-Releasing Hormone (LHRH)
7.2.4 Reolysin (Oncolytics Biotech)
7.2.5 SGI110 (Astex Pharmaceuticals)
7.2.6 OvaRex (Quest PharmaTech)
7.2.7 Polyvalent Antigen-KLH Conjugate Vaccine (MabVax Therapeutics)
7.2.8 Motolimod (VentiRx Pharmaceuticals): Toll-Like Receptor 8 Agonist
7.2.9 Cyramza (Eli Lilly): Expanding Approved Indications
7.2.10 EGEN-001 (Celsion Corporation): IL-12 Immunotherapy
7.2.11 Ganetespib and Elesclomol (Synta Pharmaceuticals)
7.2.12 ENMD-2076 (CASI Pharmaceuticals)
7.2.13 GALE-301 (Galena Biopharma): Folate Binding Protein Vaccine
7.2.14 Epacadostat (Incyte Corporation): IDO1 Inhibitor
7.2.15 AZD1775 (AstraZeneca): WEE1 Kinase Inhibitor
7.2.16 Etirinotecan Pegol (Nektar Therapeutics): Promising Phase II Results
7.2.17 Linsitinib (Astellas Pharmaceuticals): Development Discontinued?
7.2.18 Afuresertib (GlaxoSmithKline): Multiple Oncology Indications
7.2.19 Zybrestat (OXiGENE): Vascular Disrupting Agent
7.2.20 Yervoy (Bristol-Myers Squibb)
7.2.21 Alisertib (Takeda Pharmaceuticals): Aurora A Kinase Inhibitor
7.2.22 Voxtalisib with Pimasertib (Sanofi and Merck Serono)
7.2.23 Eli Lilly’s Phase II Ovarian Cancer Pipeline: LY2606368, Olaratumab & Ralimetinib
7.2.24 MK2206 (Merck & Co.): AKT Inhibitor
7.2.25 A6 Peptide (Angstrom Pharma)
7.2.26 Lifastuzumab Vedotin (Roche): Antibody Drug Conjugate
7.3 Ovarian Cancer Phase II Candidates 2015
7.3.1 VBL-111 (VBL Therapeutics): Anti-Angiogenic Agent
7.3.2 MEDI4736 (AstraZeneca)
7.3.3 OVax (AVAX Technologies)
7.3.4 ME-344 (Novogen)
7.3.5 DPX-Survivac and DPX-0907 (Immunovaccine): Two Novel Immunotherapies
8. Qualitative Analysis of the Ovarian Cancer Therapy Market 2015-2025
8.1 SWOT Analysis of the Ovarian Cancer Therapeutics Market
8.1.1 Strengths and Weaknesses of the Market
8.1.2 The Rising Incidence of Cancer
8.1.3 Drug Development Challenges
8.2 Opportunities and Threats for the Market
8.2.1 Advances in Research Open the Doors for Personalised Therapy
8.3 Regulations and Pricing Restrictions
8.4 STEP Analysis of the Ovarian Cancer Therapy Market
8.4.1 Social Factors: An Expanding Patient Population and Increasing Awareness
8.4.2 Technological Advances: DNA Sequencing of High-Grade Serous Ovarian Carcinoma
8.4.3 Economic Factors: Cost Cutting in the EU and the US
8.4.4 Political Factors: Will the Affordable Care Act Increase Patient Access to Anti-Cancer Drugs?
8.5 Porter’s Five Forces Analysis of the Ovarian Cancer Therapeutics Market
8.5.1 Rivalry Among Competitors
8.5.2 Threat of New Entrants
8.5.3 Power of Suppliers
8.5.4 Power of Buyers
8.5.5 Threat of Substitutes
9. Research Interviews
9.1 Interview with Prof. Dror Harats, CEO, VBL Therapeutics
9.1.1 Outlook for VB-111 in the Ovarian Cancer Market
9.1.2 Drivers and Restraints in the Ovarian Cancer Market
9.1.3 Trends in the Ovarian Cancer Market
9.1.4 Outlook for VBL Therapeutics in the Oncology Market
9.2 Interview with Mr Stuart Roberts, Global Head of Investor Relations, Prima BioMed
9.2.1 Outlook for CVac in the Ovarian Cancer Market
9.2.2 The Ovarian Cancer Market
9.2.3 Trends in the Ovarian Cancer Market
9.2.4 Outlook for Prima BioMed in the Oncology Market
9.3 Interview with a Representative of OXiGENE
9.3.1 Outlook for Zybrestat in the Ovarian Cancer Market
9.3.2 The Ovarian Cancer Market in 2015
9.3.3 Trends in the Ovarian Cancer Market, 2015-2025
9.3.4 Outlook for OXiGENE in the Oncology Market
10. Conclusions from the Research and Analysis
10.1 The World Ovarian Cancer Therapeutics Market in 2014
10.1.1 Leading National Markets to 2025
10.2 Trends in the Industry
10.2.1 Growing Interest in Personalised Therapy
10.2.2 Multiple Late-Stage Pipeline Drugs
10.3 Concluding Remarks
【レポート販売概要】
■ タイトル：卵巣がん治療薬の世界市場：企業動向、研究開発、収益予測■ 英文：Ovarian Cancer Drug Therapy: Companies, R&D and Revenue Forecasts 2015-2025
: Recently Approved Treatments Give High Market Potential
■ 発行日：2015年7月
■ 調査会社：visiongain
■ 商品コード：VGAIN5081914
■ 調査対象地域：グローバル
- Abbott Laboratories：市場シェア分析Abbott Laboratories Market Share Analysis Summary GlobalData’s new report, “Abbott Laboratories Market Share Analysis” provides in-depth information on Abbott Laboratories’s market position in the different medical equipment markets it operates in. The report provides Abbott Laboratories market share information in 10 key market categories – Interventional Cardiology, Infectious Immunology, Geneti …
- インドの医薬品市場：ジェネリック医薬品、OTC医薬品、特許薬、バイオシミラーWhat can be expected from the Indian Pharmaceutical market? Which areas are going to grow at the fastest rates? This visiongain report shows you potential revenues to 2026, assessing data, trends, opportunities and prospects there. Our 194-page report provides 117 tables, charts, and graphs. Discover the most lucrative areas in the industry and the future market prospects. Our new study lets you a …
- 世界主要国の血液凝固因子検査（医療機器）市場The growing cost-containment pressures in major industrialized nations and continued technological advances will radically change coagulation testing practice during the next ten years. New specific and sensitive markers of hemostasis will be increasingly used on automated instrumentation. Coagulation testing in general, and Factor Assays testing specifically, will become more standardized, offeri …
- リファビッシュ医療機器の世界市場予測（～2021年）：X線装置、超音波装置、MRI装置、CTスキャナ、核イメージングシステム、人工心肺、手術機器、CO2モニター、患者モニター、パルスオキシメーター、AED、カテーテル治療診察室、新生児集中治療装置、内視鏡The global refurbished medical equipment market is expected to reach USD 11.91 Billion by 2021 from USD 6.55 Billion in 2016, growing at a CAGR of 12.7% between 2016 and 2021. On the basis of products, the market is divided into eleven segments, namely, operating room equipment & surgical equipment, patient monitors, defibrillators, medical imaging equipment, cardiovascular & cardiology equipment, …
- 世界のサニタリーポンプ市場：サニタリー渦巻ポンプ、容積式ポンプ、特殊ポンプAbout Sanitary Pumps Sanitary pumps, also known as hygienic pumps, are used in a production line to initiate the flow of sensitive medium that is highly prone to contamination. Sanitary pumps find their application mainly in the Food and Beverage, and Pharmaceuticals and Personal Care industries, where the hygiene standards are provided at most importance. Sanitary pumps can be classified into cen …
- 若年性骨髄単球性白血病（JMML）：世界の臨床試験レビュー（2014年上半期）Juvenile Myelomonocytic Leukemia (JMML) Global Clinical Trials Review, H1, 2014 Summary GlobalData's clinical trial report, “Juvenile Myelomonocytic Leukemia (JMML) Global Clinical Trials Review, H1, 2014" provides data on the Juvenile Myelomonocytic Leukemia (JMML) clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Juvenile Myelomonocyt …
- 世界の臨床化学及び免疫診断検査市場：課題、新技術、競争環境“New Frontiers in Point-of-Care/POC Clinical Chemistry and Immunodiagnostic Testing: Business Challenges, Emerging Technologies, Competitive Landscape” is Venture Planning Group’s new report, which provides comprehensive analysis of the POC clinical chemistry markets, including their dynamics, size, growth, regulatory requirements, technological trends, competitive landscape, and …
- 世界主要国のシゲラ（赤痢菌）検査（医療機器）市場：サプライヤーシェア及び市場予測The report presents a detailed analysis of the Shigella diagnostics market in the US, Europe, (France, Germany, Italy, Spain, UK) and Japan. Current scientific views on the Shigella definition, epidemiology and etiology are reviewed. The report provides the 5-year test volume and sales forecasts by country for the following market segments: - Hospitals - Comme …
- 半導体フォトリソグラフィ用装置の世界市場2016-2020About Semiconductor Photolithography Equipment Photolithography, also known as optical lithography or UV lithography, is a method of microprocessor and printed circuit board (PCB) fabrication. The process includes transferring the image of a circuit from a photomask onto a silicon wafer. This is done by exposing the photomask and the silicon wafer to UV light and then projecting the image of the c …
- 世界のライム病検査市場The report presents a detailed analysis of the Lyme disease diagnostics market in the US, Europe (France, Germany, Italy, Spain, UK) and Japan. Current scientific views on the Lyme disease definition, epidemiology and etiology are reviewed. The report provides the 5-year test volume and sales forecasts by country for the following market segments: - Hospitals …
- 2014年戦略提言：Lime Disease診断検査市場The report presents a detailed analysis of the Lyme disease diagnostics market in the US, Europe (France, Germany, Italy, Spain, UK) and Japan. Current scientific views on the Lyme disease definition, epidemiology and etiology are reviewed. The report provides the 5-year test volume and sales forecasts by country for the following market segments: - Hospitals …
- 世界のワイヤレス充電器市場動向：Global Wireless Chargers Market 2014-2018TechNavio's analysts forecast the Global Wireless Chargers market to grow at a CAGR of 55.47 percent over the period 2013-2018. One of the key factors contributing to this market growth is the increasing demand for mobile devices. The Global Wireless Chargers market has also been witnessing the increasing adoption of wireless power technology. However, the high cost of manufacturing wireless charg …
- トラック隊列走行（プラトーニング）の世界市場予測（～2030年）“The rising number of road accidents due to driver error and increasing focus on reducing transportation operating cost will fuel the demand for the truck platooning market”The truck platooning market is projected to grow at a CAGR of 60.96% during the forecast period, and the market size is projected to grow from USD 37.6 million in 2021 to USD 2,728.7 million by 2030. The development of autonomo …
- コンピュータ支援コーディングソフトウェアの世界市場：自然言語処理ソフトウェア、構造化入力ソフトウェア、コーディングサービス、プログラムComputer-assisted coding has helped in reducing coding errors, thereby reducing healthcare costs and increasing the productivity of healthcare facilities globally. The global computer-assisted coding market is expected to grow at a CAGR of around 16% to 17% during the forecast period. This market is mainly driven by regulatory compliances, growing information content in healthcare organizations, a …
- 商用印刷サービスの世界市場：一般商用印刷、出版印刷、広告印刷About Global Commercial Printing Market The process of reproducing images, written material, or patterns for advertising and promotional purposes is called commercial printing. The various types of commercial printing processes include lithographic, gravure, screen, flexographic, and digital printing. These processes differ in the type of inks that they use and the type of pressure applied for the …
